Market closed
Tarsus Pharmaceuticals/$TARS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Ticker
$TARS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
244
Website
TARS Metrics
BasicAdvanced
$1.8B
-
-$3.70
1.00
-
Price and volume
Market cap
$1.8B
Beta
1
52-week high
$57.14
52-week low
$20.08
Average daily volume
650K
Financial strength
Current ratio
5.422
Quick ratio
5.272
Long term debt to equity
30.717
Total debt to equity
30.983
Interest coverage (TTM)
-21.54%
Management effectiveness
Return on assets (TTM)
-27.26%
Return on equity (TTM)
-59.56%
Valuation
Price to revenue (TTM)
13.028
Price to book
7.48
Price to tangible book (TTM)
7.76
Price to free cash flow (TTM)
-16.608
Growth
Revenue change (TTM)
801.96%
Earnings per share change (TTM)
-4.63%
3-year revenue growth (CAGR)
31.74%
3-year earnings per share growth (CAGR)
90.71%
What the Analysts think about TARS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Tarsus Pharmaceuticals stock.
TARS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TARS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TARS News
AllArticlesVideos
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
GlobeNewsWire·1 week ago
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Seeking Alpha·1 month ago
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tarsus Pharmaceuticals stock?
Tarsus Pharmaceuticals (TARS) has a market cap of $1.8B as of January 22, 2025.
What is the P/E ratio for Tarsus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Tarsus Pharmaceuticals (TARS) stock is 0 as of January 22, 2025.
Does Tarsus Pharmaceuticals stock pay dividends?
No, Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders as of January 22, 2025.
When is the next Tarsus Pharmaceuticals dividend payment date?
Tarsus Pharmaceuticals (TARS) stock does not pay dividends to its shareholders.
What is the beta indicator for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.